As we found that all of the MCAo-subjected animals showed comparable neurological deficits at 1 d after stroke with very low individual variations, we randomly assigned three groups for adenoviral NRG1, AdMSCs, NRG1-AdMSCs, or PBS injection and performed transplantation at 1 d post-stroke after we confirmed similar neurological outcomes by mNSS test. The gene discussed is NRG1; the disease is stroke disorder.